Abstract
Immunotherapy with antibodies against respiratory syncytial virus (RSV) is a treatment option given the absence of any vaccine or other available satisfactory treatment. We selected one of our monoclonal antibodies, RS-348, that is highly neutralizing. We showed that a single peptide (PEP3H) derived from complementarity-determining region 3 (CDR3) of its heavy chain was capable of neutralizing the virus in vitro. When intranasally administered 24 h before challenge, this peptide protected BALB/c mice against RSV lung infection. These results indicate that a single CDR can be effective against RSV infection.
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / genetics
-
Antibodies, Viral / administration & dosage*
-
Antibodies, Viral / chemistry
-
Antibodies, Viral / genetics
-
Female
-
Immunoglobulin Variable Region / administration & dosage*
-
Immunoglobulin Variable Region / chemistry
-
Immunoglobulin Variable Region / genetics
-
Immunotherapy
-
In Vitro Techniques
-
Mice
-
Mice, Inbred BALB C
-
Molecular Sequence Data
-
Neutralization Tests
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Infections / therapy
-
Respiratory Syncytial Viruses / immunology*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Viral
-
Immunoglobulin Variable Region